Increased phosphorylation of @entity1366 is associated with worse chemotherapeutic outcome and a poor prognosis in advanced XXXX .

@entity1 @entity5 @entity3962 @entity982 @entity1366 @entity2220
UNASSIGNED: Constitutive activation of @entity3962 pathway, that is activated by various stimuli including growth factors and oncogenic driver mutations, is observed in various @entity5 . However, the difference of the activated levels of the pathway is still unclear in clinical significances. The aim of this study was to investigate the effect of different @entity1366 pathway activation, assessed by the expression levels of phosphorylated (p) @entity1366 , on the prognosis of advanced @entity2220 @entity1 . @entity982 -embedded lung biopsy samples were obtained from 85 @entity2220 @entity1 . Correlation between pERK1/2 expression levels that were assessed by immunohistochemistry (IHC) analysis and oncogenic driver mutation status, clinicopathological factors, outcome from standard anticancer therapies, and prognosis was investigated. Varying levels of pERK1/2 expression were observed in 68 (80.0  %) @entity1 . The overall survival was significantly reduced in @entity1 with higher pERK1/2 expression in comparison to those with lower expression levels (P  =  0.03). In particular, higher pERK1/2 expression levels correlated with worse performance status and worse clinical outcome. Thus, the IHC analysis of pERK1/2 expression levels may predict @entity1 prognosis in advanced @entity2220 . Inhibition of @entity1366 pathway activated by various signals may improve the effects of standard chemotherapies and the clinical condition of @entity1 with @entity5 .
